Cancer epigenetics: Moving forward

Defects in chromatin modifiers and remodelers have been described both for hematological and solid malignancies, corroborating and strengthening the role of epigenetic aberrations in the etiology of cancer. Furthermore, epigenetic marks-DNA methylation, histone modifications, chromatin remodeling, a...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:PLoS genetics Ročník 14; číslo 6; s. e1007362
Hlavní autori: Nebbioso, Angela, Tambaro, Francesco Paolo, Dell’Aversana, Carmela, Altucci, Lucia
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States Public Library of Science 07.06.2018
Public Library of Science (PLoS)
Predmet:
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Biology
Biology and life sciences
Biomarkers, Tumor - genetics
Breast cancer
Cancer
Cancer genetics
Cancer research
Cancer therapies
Chromatin
Chromatin Assembly and Disassembly - genetics
Chromatin remodeling
Consortia
Deoxyribonucleic acid
Disease
Disease Progression
DNA
DNA methylation
DNA Methylation - genetics
Enzyme Inhibitors - pharmacology
Enzyme Inhibitors - therapeutic use
Enzymes - genetics
Enzymes - metabolism
Epigenesis, Genetic - drug effects
Epigenetic inheritance
Epigenetics
Epigenomics - methods
Etiology
Forecasts and trends
Gene expression
Gene Expression Regulation, Neoplastic
Genetic research
Genomes
Histone Code - genetics
Humans
Leukemia
Medicine and Health Sciences
MicroRNAs - genetics
miRNA
Molecular Targeted Therapy - methods
Mutation
Neoplasms - diagnosis
Neoplasms - drug therapy
Neoplasms - genetics
Patients
Prognosis
Review
Transcription factors
Tumorigenesis
Italy
ISSN:1553-7404, 1553-7390, 1553-7404
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Defects in chromatin modifiers and remodelers have been described both for hematological and solid malignancies, corroborating and strengthening the role of epigenetic aberrations in the etiology of cancer. Furthermore, epigenetic marks-DNA methylation, histone modifications, chromatin remodeling, and microRNA-can be considered potential markers of cancer development and progression. Here, we review whether altered epigenetic landscapes are merely a consequence of chromatin modifier/remodeler aberrations or a hallmark of cancer etiology. We critically evaluate current knowledge on causal epigenetic aberrations and examine to what extent the prioritization of (epi)genetic deregulations can be assessed in cancer as some type of genetic lesion characterizing solid cancer progression. We also discuss the multiple challenges in developing compounds targeting epigenetic enzymes (named epidrugs) for epigenetic-based therapies. The implementation of acquired knowledge of epigenetic biomarkers for patient stratification, together with the development of next-generation epidrugs and predictive models, will take our understanding and use of cancer epigenetics in diagnosis, prognosis, and treatment of cancer patients to a new level.
AbstractList Defects in chromatin modifiers and remodelers have been described both for hematological and solid malignancies, corroborating and strengthening the role of epigenetic aberrations in the etiology of cancer. Furthermore, epigenetic marks—DNA methylation, histone modifications, chromatin remodeling, and microRNA—can be considered potential markers of cancer development and progression. Here, we review whether altered epigenetic landscapes are merely a consequence of chromatin modifier/remodeler aberrations or a hallmark of cancer etiology. We critically evaluate current knowledge on causal epigenetic aberrations and examine to what extent the prioritization of (epi)genetic deregulations can be assessed in cancer as some type of genetic lesion characterizing solid cancer progression. We also discuss the multiple challenges in developing compounds targeting epigenetic enzymes (named epidrugs) for epigenetic-based therapies. The implementation of acquired knowledge of epigenetic biomarkers for patient stratification, together with the development of next-generation epidrugs and predictive models, will take our understanding and use of cancer epigenetics in diagnosis, prognosis, and treatment of cancer patients to a new level.
Defects in chromatin modifiers and remodelers have been described both for hematological and solid malignancies, corroborating and strengthening the role of epigenetic aberrations in the etiology of cancer. Furthermore, epigenetic marks-DNA methylation, histone modifications, chromatin remodeling, and microRNA-can be considered potential markers of cancer development and progression. Here, we review whether altered epigenetic landscapes are merely a consequence of chromatin modifier/remodeler aberrations or a hallmark of cancer etiology. We critically evaluate current knowledge on causal epigenetic aberrations and examine to what extent the prioritization of (epi)genetic deregulations can be assessed in cancer as some type of genetic lesion characterizing solid cancer progression. We also discuss the multiple challenges in developing compounds targeting epigenetic enzymes (named epidrugs) for epigenetic-based therapies. The implementation of acquired knowledge of epigenetic biomarkers for patient stratification, together with the development of next-generation epidrugs and predictive models, will take our understanding and use of cancer epigenetics in diagnosis, prognosis, and treatment of cancer patients to a new level.Defects in chromatin modifiers and remodelers have been described both for hematological and solid malignancies, corroborating and strengthening the role of epigenetic aberrations in the etiology of cancer. Furthermore, epigenetic marks-DNA methylation, histone modifications, chromatin remodeling, and microRNA-can be considered potential markers of cancer development and progression. Here, we review whether altered epigenetic landscapes are merely a consequence of chromatin modifier/remodeler aberrations or a hallmark of cancer etiology. We critically evaluate current knowledge on causal epigenetic aberrations and examine to what extent the prioritization of (epi)genetic deregulations can be assessed in cancer as some type of genetic lesion characterizing solid cancer progression. We also discuss the multiple challenges in developing compounds targeting epigenetic enzymes (named epidrugs) for epigenetic-based therapies. The implementation of acquired knowledge of epigenetic biomarkers for patient stratification, together with the development of next-generation epidrugs and predictive models, will take our understanding and use of cancer epigenetics in diagnosis, prognosis, and treatment of cancer patients to a new level.
Audience Academic
Author Nebbioso, Angela
Dell’Aversana, Carmela
Altucci, Lucia
Tambaro, Francesco Paolo
AuthorAffiliation Albert Einstein College of Medicine, UNITED STATES
1 Dipartimento di Medicina di Precisione, Università degli Studi della Campania “L. Vanvitelli,” Napoli, Italy
2 Struttura Semplice Dipartimentale Trapianto di Midollo Osseo-Azienda Ospedialiera di Rilievo Nazionale, Santobono-Pausilipon, Napoli, Italy
AuthorAffiliation_xml – name: 1 Dipartimento di Medicina di Precisione, Università degli Studi della Campania “L. Vanvitelli,” Napoli, Italy
– name: Albert Einstein College of Medicine, UNITED STATES
– name: 2 Struttura Semplice Dipartimentale Trapianto di Midollo Osseo-Azienda Ospedialiera di Rilievo Nazionale, Santobono-Pausilipon, Napoli, Italy
Author_xml – sequence: 1
  givenname: Angela
  orcidid: 0000-0001-5374-3527
  surname: Nebbioso
  fullname: Nebbioso, Angela
– sequence: 2
  givenname: Francesco Paolo
  surname: Tambaro
  fullname: Tambaro, Francesco Paolo
– sequence: 3
  givenname: Carmela
  surname: Dell’Aversana
  fullname: Dell’Aversana, Carmela
– sequence: 4
  givenname: Lucia
  orcidid: 0000-0002-7312-5387
  surname: Altucci
  fullname: Altucci, Lucia
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29879107$$D View this record in MEDLINE/PubMed
BookMark eNqVk9uO0zAQhiO0iD3AGyCoQEJw0WLHdhzvBdKq4lBpYSVOt9bUmaSu0rjYyQJvj0NT1KxWCOQLW_b3_-PxeE6To8Y1mCQPKZlRJunLtet8A_VsW2Ezo4RIlqV3khMqBJtKTvjRwfo4OQ1hTQgTuZL3kuNU5VJRIk-SJ3NoDPoJbm30wdaacD55765tU01K57-DL-4nd0uoAz4Y5rPky5vXn-fvppdXbxfzi8upkWnWThUr2NIInnJYFoIBA5DZkogSgYqcM2MyKViZK1B5ybGgWErKBUHIDApg7Cx5vPPd1i7oIb2gUyJJnlGl8kgsdkThYK233m7A_9QOrP694XylwccUatRY8DSlgqoUOM9zo8AwIzlFXiiaL7Po9WqI1i03WBhsWg_1yHR80tiVrty1FkrRLOsNng8G3n3rMLR6Y4PBuoYGXdffW6Q5iRVII_r0Bnp7dgNVQUzANqWLcU1vqi8E5zGsymikZrdQcRS4sSZ-kdLG_ZHgxUgQmRZ_tBV0IejFp4__wX74d_bq65h9dsCuEOp2FVzdtdY1YQw-OqzKn3LsP2wEzneA8S4Ej6U2toXeJz6DrTUluu-O_QPrvjv00B1RzG-I9_5_lf0CLhAP8Q
CitedBy_id crossref_primary_10_1007_s12017_025_08830_8
crossref_primary_10_2217_bmm_2020_0095
crossref_primary_10_3389_fonc_2022_1071100
crossref_primary_10_1080_15384101_2021_1956090
crossref_primary_10_3390_cancers14010041
crossref_primary_10_1016_j_bbrc_2023_08_003
crossref_primary_10_1016_j_semcancer_2020_09_012
crossref_primary_10_1038_s41401_021_00796_0
crossref_primary_10_1016_j_canlet_2025_218035
crossref_primary_10_1002_ijc_33681
crossref_primary_10_3390_ijms22147350
crossref_primary_10_1016_j_bcp_2022_115334
crossref_primary_10_2217_epi_2018_0177
crossref_primary_10_3389_fphar_2018_01349
crossref_primary_10_1155_2022_1807386
crossref_primary_10_3390_ijms25020766
crossref_primary_10_1007_s12033_024_01264_w
crossref_primary_10_1016_j_bbcan_2020_188454
crossref_primary_10_2147_IJGM_S350783
crossref_primary_10_1002_mco2_582
crossref_primary_10_1016_j_pharmthera_2022_108334
crossref_primary_10_3390_cancers14030560
crossref_primary_10_1158_2159_8290_CD_21_1059
crossref_primary_10_3389_fgene_2022_805960
crossref_primary_10_3390_cancers11091343
crossref_primary_10_3390_molecules24162899
crossref_primary_10_1055_s_0043_1776127
crossref_primary_10_1016_j_taap_2021_115569
crossref_primary_10_1002_ange_202425599
crossref_primary_10_1038_s41698_021_00173_4
crossref_primary_10_3389_fmed_2025_1613722
crossref_primary_10_1093_nar_gky814
crossref_primary_10_1080_15592294_2019_1664229
crossref_primary_10_1080_13543784_2023_2290064
crossref_primary_10_1021_acs_chemrestox_5c00055
crossref_primary_10_3390_ijms23126516
crossref_primary_10_1007_s12672_023_00843_8
crossref_primary_10_1016_j_isci_2024_111614
crossref_primary_10_1016_j_ejso_2019_02_005
crossref_primary_10_3389_fgene_2021_703883
crossref_primary_10_1016_j_plrev_2024_06_005
crossref_primary_10_3389_fonc_2022_964902
crossref_primary_10_32604_oncologie_2022_027545
crossref_primary_10_1186_s12935_024_03322_4
crossref_primary_10_1093_ije_dyab044
crossref_primary_10_3389_fgene_2023_1084869
crossref_primary_10_1093_molehr_gaac024
crossref_primary_10_1186_s13046_022_02297_2
crossref_primary_10_1186_s13027_023_00492_0
crossref_primary_10_3390_ijms24065494
crossref_primary_10_1002_2211_5463_12973
crossref_primary_10_1155_2022_5490461
crossref_primary_10_3390_cells8080929
crossref_primary_10_1038_s41568_025_00845_4
crossref_primary_10_2147_CMAR_S252772
crossref_primary_10_1038_s41579_020_0382_3
crossref_primary_10_1371_journal_pone_0236192
crossref_primary_10_3390_molecules28031217
crossref_primary_10_3389_fimmu_2022_1043667
crossref_primary_10_1007_s10585_025_10364_z
crossref_primary_10_1038_s41598_021_01080_1
crossref_primary_10_1002_ijc_33912
crossref_primary_10_3390_diagnostics11050851
crossref_primary_10_1016_j_ajpath_2024_07_023
crossref_primary_10_1186_s13073_019_0703_1
crossref_primary_10_3390_cells12141882
crossref_primary_10_1007_s00018_019_03098_1
crossref_primary_10_1186_s12885_021_08800_w
crossref_primary_10_3389_fcell_2020_00870
crossref_primary_10_1080_15592294_2019_1638701
crossref_primary_10_1093_nar_gkac147
crossref_primary_10_3390_ijms20225654
crossref_primary_10_2217_epi_2023_0181
crossref_primary_10_3390_life12122010
crossref_primary_10_1016_j_scitotenv_2021_151218
crossref_primary_10_3390_genes14010100
crossref_primary_10_3390_pathophysiology28030028
crossref_primary_10_1186_s13059_023_03094_6
crossref_primary_10_1016_j_yexcr_2023_113563
crossref_primary_10_3389_fcell_2020_603837
crossref_primary_10_3389_fcell_2023_1086573
crossref_primary_10_1038_s41467_021_25326_8
crossref_primary_10_1186_s13148_021_01047_z
crossref_primary_10_2217_epi_2022_0143
crossref_primary_10_3390_ijms20236077
crossref_primary_10_1186_s13027_023_00558_z
crossref_primary_10_3390_cancers15133506
crossref_primary_10_1186_s13287_021_02521_4
crossref_primary_10_3390_jpm12091428
crossref_primary_10_1002_advs_202304329
crossref_primary_10_3389_fcell_2020_00004
crossref_primary_10_1186_s11658_021_00258_9
crossref_primary_10_1016_j_drup_2021_100796
crossref_primary_10_1016_j_csbj_2024_02_029
crossref_primary_10_1016_j_semcancer_2021_12_007
crossref_primary_10_1111_1348_0421_12926
crossref_primary_10_3389_fphar_2019_00038
crossref_primary_10_1007_s10555_023_10117_y
crossref_primary_10_1038_s41388_024_03047_8
crossref_primary_10_1016_j_apsb_2020_09_016
crossref_primary_10_1016_j_biopha_2022_114077
crossref_primary_10_1038_s41374_020_0466_8
crossref_primary_10_1186_s13148_022_01323_6
crossref_primary_10_3389_fonc_2021_741746
crossref_primary_10_3892_mmr_2019_10634
crossref_primary_10_1016_j_prp_2022_154231
crossref_primary_10_1016_j_bbcan_2025_189337
crossref_primary_10_2217_epi_2023_0281
crossref_primary_10_1093_bib_bbab312
crossref_primary_10_1016_j_canep_2020_101873
crossref_primary_10_1002_jcla_23537
crossref_primary_10_3390_biomedicines10102567
crossref_primary_10_2174_0929867329666220922102949
crossref_primary_10_1016_j_trsl_2023_10_001
crossref_primary_10_3390_jcm10091931
crossref_primary_10_1016_j_chemosphere_2019_03_096
crossref_primary_10_3390_ijms20184497
crossref_primary_10_1002_anie_202425599
crossref_primary_10_7759_cureus_43960
crossref_primary_10_31083_j_fbs1504013
crossref_primary_10_1002_mc_23559
crossref_primary_10_2174_0115734064329669241007060848
crossref_primary_10_3892_ijmm_2023_5284
crossref_primary_10_1038_s41419_019_1604_3
crossref_primary_10_3390_ph16010119
crossref_primary_10_1007_s11356_021_14849_8
crossref_primary_10_1016_j_heliyon_2024_e35686
crossref_primary_10_1007_s00216_019_01583_x
crossref_primary_10_15252_emmm_201810116
crossref_primary_10_1038_s41419_019_1575_4
crossref_primary_10_3390_genes14040873
crossref_primary_10_1016_j_jbc_2025_110352
crossref_primary_10_1007_s43032_021_00516_3
crossref_primary_10_1016_j_biopha_2023_115753
crossref_primary_10_3390_ijms21031102
crossref_primary_10_1016_j_biopha_2022_114025
crossref_primary_10_1111_iju_15042
crossref_primary_10_1016_j_taap_2020_115212
crossref_primary_10_3389_fonc_2024_1464125
crossref_primary_10_1007_s40944_023_00773_x
crossref_primary_10_3389_fphys_2021_650124
crossref_primary_10_1038_s41419_021_03455_8
crossref_primary_10_3390_ijms25116168
crossref_primary_10_1007_s00259_023_06546_0
crossref_primary_10_1016_j_lfs_2020_117289
crossref_primary_10_1016_j_jep_2021_114413
crossref_primary_10_1016_j_bbrc_2018_12_176
crossref_primary_10_1096_fj_201900233RR
crossref_primary_10_3390_ijms22063151
crossref_primary_10_3390_ijms21249681
crossref_primary_10_1016_j_cellsig_2020_109886
crossref_primary_10_1016_j_biopha_2022_113180
crossref_primary_10_2174_0929867328666211108105214
crossref_primary_10_1080_15384047_2024_2373447
crossref_primary_10_3390_cells11152293
crossref_primary_10_3389_fonc_2020_557157
crossref_primary_10_3389_fendo_2020_00485
crossref_primary_10_3389_fonc_2023_1333812
crossref_primary_10_1093_humrep_deae066
crossref_primary_10_1016_j_archoralbio_2022_105468
crossref_primary_10_1038_s41418_022_01037_5
crossref_primary_10_2217_fon_2019_0760
crossref_primary_10_1007_s12672_025_02928_y
crossref_primary_10_1042_BST20210725
crossref_primary_10_3390_nu13072428
crossref_primary_10_1016_j_preteyeres_2021_101030
crossref_primary_10_3390_cancers13051102
crossref_primary_10_1016_j_sajb_2023_12_005
crossref_primary_10_1098_rsob_190056
crossref_primary_10_1007_s10549_021_06325_1
crossref_primary_10_1186_s13148_024_01769_w
crossref_primary_10_3390_cancers14194797
crossref_primary_10_1007_s10719_022_10042_2
crossref_primary_10_1007_s11102_025_01522_3
crossref_primary_10_1186_s13072_023_00508_4
crossref_primary_10_3389_freae_2023_1241583
crossref_primary_10_1097_MD_0000000000026551
crossref_primary_10_3390_cancers12123760
crossref_primary_10_3390_cancers16183152
crossref_primary_10_1053_j_gastro_2022_05_007
crossref_primary_10_3389_fgene_2021_566168
crossref_primary_10_1155_2021_2719172
crossref_primary_10_1007_s12672_024_01412_3
crossref_primary_10_1186_s13072_024_00554_6
crossref_primary_10_1007_s10565_021_09691_0
crossref_primary_10_4155_fmc_2018_0477
crossref_primary_10_1186_s12885_020_06982_3
crossref_primary_10_1089_dna_2018_4358
crossref_primary_10_3390_ijms22010401
crossref_primary_10_1002_cac2_12374
crossref_primary_10_1016_j_tranon_2025_102479
crossref_primary_10_1186_s13048_024_01427_y
crossref_primary_10_3389_fgene_2020_00903
crossref_primary_10_1038_s41397_019_0138_5
crossref_primary_10_1016_j_bbadis_2022_166552
crossref_primary_10_1016_j_drudis_2019_09_007
crossref_primary_10_1080_07391102_2023_2293267
crossref_primary_10_1042_BSR20180731
crossref_primary_10_1096_fj_202300626R
crossref_primary_10_3389_fonc_2019_00246
crossref_primary_10_3389_fonc_2021_731535
crossref_primary_10_2174_0929867330666230607124803
crossref_primary_10_1002_cbin_12145
crossref_primary_10_1111_vco_12624
crossref_primary_10_1186_s40164_018_0116_7
crossref_primary_10_3390_ijms23105654
crossref_primary_10_1016_j_mehy_2021_110614
crossref_primary_10_1038_s41525_022_00340_x
crossref_primary_10_1016_j_prp_2024_155619
crossref_primary_10_1016_j_phrs_2022_106587
crossref_primary_10_1155_2018_2931049
crossref_primary_10_1530_REP_18_0449
crossref_primary_10_1038_s41598_023_46107_x
crossref_primary_10_3389_fimmu_2022_803962
crossref_primary_10_1038_s41380_019_0601_3
crossref_primary_10_3389_fcell_2022_981075
crossref_primary_10_3390_cells11030468
crossref_primary_10_1016_j_genrep_2021_101188
crossref_primary_10_1155_2022_1429869
crossref_primary_10_3390_cancers14225474
crossref_primary_10_3390_ijms24054539
crossref_primary_10_3389_fcell_2021_703969
crossref_primary_10_1155_2022_6530884
crossref_primary_10_1016_j_lfs_2019_117114
crossref_primary_10_1146_annurev_biochem_062917_011840
crossref_primary_10_1186_s12943_025_02269_y
crossref_primary_10_1093_hmg_ddz261
crossref_primary_10_1016_j_bulcan_2020_08_004
crossref_primary_10_3390_ijms22158324
crossref_primary_10_3389_fonc_2022_824190
crossref_primary_10_1080_10408444_2023_2250387
crossref_primary_10_3389_fonc_2022_848163
crossref_primary_10_1186_s13046_020_01584_0
crossref_primary_10_3389_fonc_2020_620641
crossref_primary_10_1007_s00432_024_06051_3
crossref_primary_10_1016_j_bmc_2022_117067
crossref_primary_10_70749_ijbr_v3i1_635
crossref_primary_10_3389_fphar_2021_690057
crossref_primary_10_3390_molecules26175414
crossref_primary_10_1111_exd_14392
crossref_primary_10_3389_fonc_2021_736694
crossref_primary_10_3390_cells10051080
crossref_primary_10_1186_s40478_023_01619_5
crossref_primary_10_1055_a_2119_3229
crossref_primary_10_1007_s12672_022_00579_x
crossref_primary_10_3390_ijms22041964
crossref_primary_10_3390_ijms25105177
crossref_primary_10_3389_fphar_2022_907031
crossref_primary_10_3390_ijms24010549
crossref_primary_10_3390_cancers15092661
crossref_primary_10_1016_j_lfs_2020_117417
crossref_primary_10_1186_s13148_021_01199_y
crossref_primary_10_1038_s41419_023_05869_y
crossref_primary_10_3390_cimb46050282
crossref_primary_10_1515_biol_2022_0992
crossref_primary_10_3389_fphar_2023_1086309
crossref_primary_10_1038_s41388_020_1270_z
crossref_primary_10_2147_CMAR_S311548
crossref_primary_10_3389_fgene_2023_1211376
crossref_primary_10_3389_fonc_2022_849024
crossref_primary_10_1007_s00018_018_2924_7
crossref_primary_10_3390_cancers13164084
crossref_primary_10_1002_mas_21865
crossref_primary_10_1007_s12291_020_00888_4
crossref_primary_10_1007_s00044_024_03206_2
crossref_primary_10_1002_bies_202000262
crossref_primary_10_1038_s44319_024_00290_8
crossref_primary_10_3389_fonc_2019_01029
crossref_primary_10_3389_fphys_2022_998424
crossref_primary_10_1016_j_biocel_2023_106502
crossref_primary_10_1016_j_jinorgbio_2018_11_008
crossref_primary_10_3892_mmr_2022_12640
crossref_primary_10_3389_fphar_2021_702360
crossref_primary_10_1016_j_clon_2022_02_013
crossref_primary_10_1016_j_jhep_2019_04_003
crossref_primary_10_1080_10408398_2021_1968786
crossref_primary_10_1007_s13577_021_00636_7
crossref_primary_10_1097_MD_0000000000024449
crossref_primary_10_1177_2040622321997259
crossref_primary_10_2147_DDDT_S239158
crossref_primary_10_3390_cancers12030682
crossref_primary_10_1186_s13104_025_07437_3
crossref_primary_10_2174_0115680266299112240514103048
crossref_primary_10_3390_ijms25094874
crossref_primary_10_3390_ijms21249514
crossref_primary_10_3892_mmr_2020_10933
crossref_primary_10_2217_epi_2020_0136
crossref_primary_10_1016_j_bjpt_2024_101170
crossref_primary_10_1016_j_canlet_2019_12_029
crossref_primary_10_1038_s41392_023_01442_3
crossref_primary_10_1186_s12967_022_03600_7
crossref_primary_10_3389_fgene_2019_01306
crossref_primary_10_3390_ijms26136531
crossref_primary_10_3390_ijms24087206
crossref_primary_10_1155_2022_3261213
crossref_primary_10_1080_14789450_2025_2491357
crossref_primary_10_3390_cancers14153743
crossref_primary_10_1186_s12943_024_02069_w
crossref_primary_10_3389_fgene_2022_897123
crossref_primary_10_2217_epi_2019_0312
crossref_primary_10_1080_15265161_2020_1863516
crossref_primary_10_3390_ijms232314610
Cites_doi 10.1038/nm.2251
10.1172/JCI78440
10.1038/bjc.2011.156
10.1126/science.aad9780
10.1038/ncomms6899
10.1007/s10549-014-3089-1
10.1038/ncomms10751
10.1007/s13402-015-0239-3
10.1073/pnas.1707375114
10.1182/blood-2013-03-487884
10.1016/j.anndiagpath.2011.04.008
10.1038/s41467-017-01251-7
10.1182/blood.V91.9.3134
10.5306/wjco.v5.i3.509
10.1182/blood-2010-07-298349
10.1002/gcc.2870020308
10.1038/nature12108
10.1126/science.aal2380
10.1002/pbc.26251
10.1016/j.leukres.2013.07.016
10.1016/j.celrep.2016.08.082
10.1016/j.molcel.2015.02.014
10.1016/j.mce.2011.12.020
10.2350/14-07-1531-MISC.1
10.1038/35057062
10.1016/j.stem.2016.10.019
10.1038/sj.onc.1205706
10.1038/nrc3239
10.1038/nrc3068
10.1038/nrg3542
10.1038/srep33435
10.1038/ncomms11938
10.1128/MCB.21.10.3598-3603.2001
10.1186/s13072-015-0050-4
10.1038/nrg2752
10.1073/pnas.0509014102
10.1016/j.tig.2015.12.001
10.1080/2162402X.2016.1219008
10.4161/epi.27322
10.1038/nrc.2016.83
10.1016/j.coi.2015.10.009
10.1038/489046a
10.1038/nm.3832
10.1016/j.cell.2011.02.013
10.1016/j.ajhg.2011.11.029
10.1158/1535-7163.MCT-12-0721
10.1158/0008-5472.CAN-08-3907
10.3171/jns.1990.73.5.0710
10.1186/bcr3127
10.1038/onc.2014.298
10.1128/MCB.22.16.5975-5988.2002
10.1038/1831654a0
10.1038/nbt.2282
10.1007/s10549-014-3037-0
10.1016/j.ccr.2010.12.014
10.1016/j.ccell.2015.03.001
10.1016/j.immuni.2016.10.021
10.1038/msb.2011.95
10.1136/bmjopen-2015-010243
10.1016/j.molcel.2013.02.013
10.1038/nrc3130
10.1002/pbc.26218
10.1038/nature11606
10.1186/s13059-017-1177-3
10.1038/s41598-017-06790-z
10.1016/j.gde.2005.01.005
10.1097/NEN.0b013e31822146ca
10.1016/j.ajhg.2010.01.013
10.1258/ebm.2011.011007
10.1056/NEJMoa1301689
10.1158/1078-0432.CCR-08-1981
10.1038/ng.3291
10.1186/gb-2007-8-10-r214
10.1101/gr.6665407
10.1016/j.ccr.2009.12.042
10.1126/science.1169786
10.1182/blood-2012-05-429050
10.1016/j.ccr.2012.06.008
10.1016/j.cmet.2017.02.003
10.2144/000113837
10.1182/blood-2010-04-279539
10.1186/1471-2164-14-643
10.1016/j.celrep.2016.10.054
10.1038/nature14248
10.1038/nature13981
10.1038/nature11412
10.1016/j.ccell.2016.09.014
10.1186/s13059-015-0723-0
10.1038/jhg.2016.89
10.1200/JCO.2008.18.1370
10.1016/j.ccr.2009.12.045
10.2217/epi-2016-0015
10.1038/nature11247
10.18632/oncotarget.10033
10.1016/S0092-8674(00)81683-9
10.1186/bcr2257
10.1016/j.ccell.2016.03.009
10.1172/JCI64400
10.1038/onc.2013.37
10.1182/blood-2015-09-665018
10.1126/science.aah6893
10.1097/PAS.0b013e3182196a39
10.1182/blood-2013-04-427724
10.1016/j.molonc.2015.10.008
10.1200/JCO.2013.55.0491
10.3892/etm.2013.915
10.1038/ng.2443
10.1038/leu.2014.252
10.1158/1078-0432.CCR-12-2037
10.1128/MCB.15.4.1974
10.1016/j.cell.2016.12.002
10.1038/labinvest.2010.66
10.1016/j.cell.2017.01.021
10.3389/fped.2017.00004
10.1073/pnas.1303800110
10.1186/1471-2407-9-217
10.1016/j.cell.2013.09.053
10.1016/j.chembiol.2017.05.024
10.1016/S1470-2045(15)70114-2
10.1186/s13148-016-0222-5
10.1200/JCO.2010.30.1010
10.1186/s13059-016-0944-x
10.1016/j.celrep.2016.10.057
10.1038/sj.leu.2403396
10.1101/gr.180240.114
10.1016/j.leukres.2013.05.012
10.1016/j.celrep.2014.08.024
10.1038/s41598-017-12010-5
10.1016/j.cell.2013.03.008
10.1038/86515
10.1016/j.immuni.2016.10.032
10.1002/pbc.24315
10.1186/s13148-016-0201-x
10.1016/j.ccell.2016.02.001
10.1371/journal.pone.0111840
10.1038/463596b
10.1038/nmeth.1557
10.1007/s10549-007-9620-x
10.1016/j.ccr.2007.04.009
10.1186/s13073-014-0066-6
10.1038/35057157
10.1158/0008-5472.CAN-05-1896
10.4161/epi.22561
10.1073/pnas.250492697
10.18632/oncotarget.14150
10.1038/ng.2928
ContentType Journal Article
Copyright COPYRIGHT 2018 Public Library of Science
2018 Nebbioso et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2018 Nebbioso et al 2018 Nebbioso et al
Copyright_xml – notice: COPYRIGHT 2018 Public Library of Science
– notice: 2018 Nebbioso et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2018 Nebbioso et al 2018 Nebbioso et al
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
IOV
ISN
ISR
3V.
7QP
7QR
7SS
7TK
7TM
7TO
7X7
7XB
88E
8FD
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7P
P64
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
RC3
7X8
5PM
DOA
DOI 10.1371/journal.pgen.1007362
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Opposing Viewpoints
Gale In Context: Canada
Gale In Context: Science
ProQuest Central (Corporate)
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Entomology Abstracts (Full archive)
Neurosciences Abstracts
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
Health & Medical Collection (Alumni Edition)
Medical Database
Biological Science Database
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Genetics Abstracts
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
AIDS and Cancer Research Abstracts
Chemoreception Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Entomology Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database
MEDLINE



MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1553-7404
ExternalDocumentID 2070861998
oai_doaj_org_article_ed42215192a4488c9ac3c741e4d918b6
PMC5991666
A544991961
29879107
10_1371_journal_pgen_1007362
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GeographicLocations Italy
GeographicLocations_xml – name: Italy
GrantInformation_xml – fundername: Worldwide Cancer Research
  grantid: 15-1002
GroupedDBID ---
123
29O
2WC
53G
5VS
7X7
88E
8FE
8FH
8FI
8FJ
AAFWJ
AAUCC
AAWOE
AAYXX
ABDBF
ABUWG
ACCTH
ACGFO
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADRAZ
AEAQA
AENEX
AFFHD
AFKRA
AFPKN
AHMBA
ALMA_UNASSIGNED_HOLDINGS
AOIJS
B0M
BAIFH
BAWUL
BBNVY
BBTPI
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
BWKFM
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAP
EAS
EBD
EBS
EJD
EMK
EMOBN
ESX
F5P
FPL
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
IAO
IGS
IHR
IHW
INH
INR
IOV
ISN
ISR
ITC
KQ8
LK8
M1P
M48
M7P
O5R
O5S
OK1
OVT
P2P
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
PV9
QF4
QN7
RNS
RPM
RZL
SV3
TR2
TUS
UKHRP
WOW
XSB
~8M
ALIPV
C1A
CGR
CUY
CVF
ECM
EIF
H13
IPNFZ
NPM
RIG
WOQ
3V.
7QP
7QR
7SS
7TK
7TM
7TO
7XB
8FD
8FK
AZQEC
DWQXO
FR3
GNUQQ
H94
K9.
P64
PKEHL
PQEST
PQUKI
PRINS
RC3
7X8
PUEGO
5PM
AAPBV
ABPTK
M~E
ID FETCH-LOGICAL-c726t-93d3bc5424abd53a3aa76b05fea15843cc6753f89a98f4ed1ef71450ea6ce5a33
IEDL.DBID M7P
ISICitedReferencesCount 371
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000440484200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1553-7404
1553-7390
IngestDate Sun Oct 01 00:20:31 EDT 2023
Fri Oct 03 12:52:06 EDT 2025
Tue Nov 04 01:51:42 EST 2025
Thu Sep 04 15:40:08 EDT 2025
Tue Oct 07 06:38:51 EDT 2025
Tue Nov 11 10:29:51 EST 2025
Tue Nov 04 17:59:12 EST 2025
Thu Nov 13 14:56:19 EST 2025
Thu Nov 13 14:48:23 EST 2025
Thu Nov 13 14:16:51 EST 2025
Thu May 22 21:22:08 EDT 2025
Mon Jul 21 06:03:15 EDT 2025
Tue Nov 18 21:57:45 EST 2025
Sat Nov 29 06:34:51 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
License This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Creative Commons Attribution License
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c726t-93d3bc5424abd53a3aa76b05fea15843cc6753f89a98f4ed1ef71450ea6ce5a33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
The authors have declared that no competing interests exist.
ORCID 0000-0001-5374-3527
0000-0002-7312-5387
OpenAccessLink https://www.proquest.com/docview/2070861998?pq-origsite=%requestingapplication%
PMID 29879107
PQID 2070861998
PQPubID 1436339
ParticipantIDs plos_journals_2070861998
doaj_primary_oai_doaj_org_article_ed42215192a4488c9ac3c741e4d918b6
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5991666
proquest_miscellaneous_2052805532
proquest_journals_2070861998
gale_infotracmisc_A544991961
gale_infotracacademiconefile_A544991961
gale_incontextgauss_ISR_A544991961
gale_incontextgauss_ISN_A544991961
gale_incontextgauss_IOV_A544991961
gale_healthsolutions_A544991961
pubmed_primary_29879107
crossref_citationtrail_10_1371_journal_pgen_1007362
crossref_primary_10_1371_journal_pgen_1007362
PublicationCentury 2000
PublicationDate 20180607
PublicationDateYYYYMMDD 2018-06-07
PublicationDate_xml – month: 6
  year: 2018
  text: 20180607
  day: 7
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: San Francisco
– name: San Francisco, CA USA
PublicationTitle PLoS genetics
PublicationTitleAlternate PLoS Genet
PublicationYear 2018
Publisher Public Library of Science
Public Library of Science (PLoS)
Publisher_xml – name: Public Library of Science
– name: Public Library of Science (PLoS)
References D Ramskold (ref131) 2012; 30
N Cancer Genome Atlas (ref64) 2012; 490
SO Dyke (ref141) 2015; 16
CH Waddington (ref3) 1959; 183
T Okuda (ref48) 1998; 91
T Cesuroglu (ref142) 2016; 6
MT McCabe (ref13) 2012; 492
AC Queiros (ref34) 2016; 30
SE Elsheikh (ref73) 2009; 69
G Judes (ref75) 2016; 8
C Jeronimo (ref70) 2008; 109
M Fagny (ref139) 2017; 114
AC Winters (ref12) 2017; 5
L Altucci (ref143) 2016; 8
B Maher (ref127) 2012; 489
JD McPherson (ref2) 2001; 409
X Agirre (ref55) 2015; 25
R Margueron (ref16) 2010; 11
BA Walker (ref56) 2011; 117
G Plitas (ref98) 2016; 45
S Meyers (ref49) 1995; 15
A Ptasinska (ref51) 2014; 8
MA Goodell (ref23) 2013; 121
J Veeck (ref68) 2009; 9
E de Rinaldis (ref79) 2013; 14
SL Topalian (ref97) 2015; 27
AK Bergmann (ref41) 2017; 64
C Roadmap Epigenomics (ref10) 2015; 518
J Moreaux (ref58) 2012; 11
E Fratta (ref60) 2016; 7
Y Wei (ref87) 2014; 147
PG Richardson (ref59) 2016; 127
MA Healey (ref74) 2014; 147
JA Hanna (ref88) 2012; 52
A Nebbioso (ref24) 2017; 7
MF Kaiser (ref54) 2013; 122
JA Biegel (ref107) 1990; 73
R Margueron (ref5) 2005; 15
OA Stefansson (ref66) 2012; 7
AF Rendeiro (ref38) 2016; 7
RT Kurmasheva (ref121) 2017; 64
J Chai (ref113) 2005; 65
W Xu (ref19) 2011; 19
JA Simon (ref15) 2013; 49
YG Tak (ref140) 2015; 8
D Hanahan (ref6) 2000; 100
V Onuchic (ref91) 2016; 17
NO Chimge (ref77) 2016; 7
RP Schuyler (ref31) 2016; 17
S Karsli-Ceppioglu (ref72) 2017; 7
Y Tomita (ref102) 2016; 5
C Blenkiron (ref78) 2007; 8
Q Mu (ref44) 2013; 37
G Kungulovski (ref144) 2016; 32
MJ Li (ref138) 2017; 18
AJ Lowery (ref83) 2009; 11
R Villa (ref61) 2007; 11
P Ramos (ref22) 2014; 46
M Kulis (ref35) 2012; 44
H Shen (ref26) 2013; 153
E Toska (ref100) 2017; 355
ST Sredni (ref106) 2015; 18
S Dey (ref63) 2014; 5
I Fkih M'hamed (ref82) 2015; 38
SK Knutson (ref62) 2014; 9
DM Pardoll (ref94) 2012; 12
AC Queiros (ref37) 2015; 29
CJ Guidi (ref109) 2001; 21
NR Wray (ref146) 2007; 17
AA Singh (ref20) 2017; 8
C Stirzaker (ref65) 2015; 6
E van Schooneveld (ref81) 2012; 14
EC Douglass (ref108) 1990; 2
M Hasselblatt (ref105) 2011; 35
BG Wilson (ref119) 2011; 11
RS Lee (ref122) 2012; 122
S Venneti (ref115) 2011; 70
SK Knutson (ref120) 2013; 110
H Dvinge (ref80) 2013; 497
A Piunti (ref11) 2016; 352
M Kulis (ref36) 2015; 47
J Torchia (ref124) 2015; 16
S Adams (ref92) 2014; 32
PN Munster (ref101) 2011; 104
CW Roberts (ref110) 2000; 97
PM Cromm (ref145) 2017; 24
C Jochems (ref93) 2011; 236
CW Chen (ref42) 2015; 21
MW Kieran (ref123) 2012; 59
JH Martens (ref39) 2010; 17
DH Munn (ref95) 2016; 39
R Schneppenheim (ref104) 2010; 86
SM Park (ref45) 2015; 125
JS Parker (ref90) 2009; 27
F Buchi (ref46) 2014; 9
A Mandoli (ref50) 2016; 17
PM Visscher (ref147) 2012; 90
T Mazor (ref133) 2016; 29
D Hnisz (ref128) 2013; 155
SB Baylin (ref17) 2011; 11
A Mathe (ref71) 2016; 6
DH Spencer (ref33) 2017; 168
T Pabst (ref53) 2001; 7
CH Waddington (ref4) 2012; 41
M Farlik (ref30) 2016; 19
B Gruhn (ref43) 2013; 37
I Comet (ref14) 2016; 16
TJ Ley (ref32) 2013; 368
A Abbott (ref8) 2010; 463
E Shapiro (ref132) 2013; 14
J Veeck (ref67) 2010; 28
S Gadd (ref118) 2010; 90
MJ Fackler (ref69) 2009; 15
YJ He (ref86) 2013; 5
EL Mora-Blanco (ref117) 2014; 33
WA Flavahan (ref18) 2017; 357
Z Jagani (ref116) 2010; 16
PD Johann (ref125) 2016; 29
U Sharma (ref28) 2017; 25
S Kurozumi (ref89) 2017; 62
T Witte (ref126) 2014; 6
ZK Zhang (ref112) 2002; 22
E Martinez-Garcia (ref57) 2011; 117
A Steube (ref25) 2017; 8
DR Cochrane (ref84) 2012; 355
F Matarese (ref136) 2011; 7
A Tonks (ref52) 2004; 18
QY Zhao (ref76) 2016; 8
M Conte (ref137) 2012; 18
BW Carey (ref29) 2015; 518
F Tang (ref130) 2011; 8
S Kriaucionis (ref135) 2009; 324
A Sledzinska (ref96) 2015; 9
J Finlay-Schultz (ref85) 2015; 34
HG Stunnenberg (ref7) 2016; 167
EP Consortium (ref9) 2012; 489
MS Isakoff (ref114) 2005; 102
ES Lander (ref1) 2001; 409
JS You (ref27) 2012; 22
SJ Clark (ref134) 2016; 17
D Hanahan (ref21) 2011; 144
D Hnisz (ref129) 2015; 58
N Savage (ref103) 2012; 16
BL Betz (ref111) 2002; 21
M De Simone (ref99) 2016; 45
K Wang (ref40) 2010; 17
JH Martens (ref47) 2012; 120
References_xml – volume: 16
  start-page: 1429
  year: 2010
  ident: ref116
  article-title: Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway
  publication-title: Nat Med
  doi: 10.1038/nm.2251
– volume: 125
  start-page: 1286
  year: 2015
  ident: ref45
  article-title: Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program
  publication-title: J Clin Invest
  doi: 10.1172/JCI78440
– volume: 104
  start-page: 1828
  year: 2011
  ident: ref101
  article-title: A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2011.156
– volume: 352
  year: 2016
  ident: ref11
  article-title: Epigenetic balance of gene expression by Polycomb and COMPASS families
  publication-title: Science
  doi: 10.1126/science.aad9780
– volume: 6
  start-page: 5899
  year: 2015
  ident: ref65
  article-title: Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value
  publication-title: Nat Commun
  doi: 10.1038/ncomms6899
– volume: 147
  start-page: 639
  year: 2014
  ident: ref74
  article-title: Association of H3K9me3 and H3K27me3 repressive histone marks with breast cancer subtypes in the Nurses' Health Study
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-014-3089-1
– volume: 7
  start-page: 10751
  year: 2016
  ident: ref77
  article-title: RUNX1 prevents oestrogen-mediated AXIN1 suppression and beta-catenin activation in ER-positive breast cancer
  publication-title: Nat Commun
  doi: 10.1038/ncomms10751
– volume: 38
  start-page: 433
  year: 2015
  ident: ref82
  article-title: Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers
  publication-title: Cell Oncol (Dordr)
  doi: 10.1007/s13402-015-0239-3
– volume: 114
  start-page: E7841
  year: 2017
  ident: ref139
  article-title: Exploring regulation in tissues with eQTL networks
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1707375114
– volume: 122
  start-page: 219
  year: 2013
  ident: ref54
  article-title: Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma
  publication-title: Blood
  doi: 10.1182/blood-2013-03-487884
– volume: 16
  start-page: 504
  year: 2012
  ident: ref103
  article-title: Molecularly confirmed primary malignant rhabdoid tumor of the urinary bladder: implications of accurate diagnosis
  publication-title: Ann Diagn Pathol
  doi: 10.1016/j.anndiagpath.2011.04.008
– volume: 8
  start-page: 1303
  year: 2017
  ident: ref25
  article-title: High-intensity UV laser ChIP-seq for the study of protein-DNA interactions in living cells
  publication-title: Nat Commun
  doi: 10.1038/s41467-017-01251-7
– volume: 91
  start-page: 3134
  year: 1998
  ident: ref48
  article-title: Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors
  publication-title: Blood
  doi: 10.1182/blood.V91.9.3134
– volume: 5
  start-page: 509
  year: 2014
  ident: ref63
  article-title: Preventing breast cancer in LMICs via screening and/or early detection: The real and the surreal
  publication-title: World J Clin Oncol
  doi: 10.5306/wjco.v5.i3.509
– volume: 117
  start-page: 211
  year: 2011
  ident: ref57
  article-title: The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells
  publication-title: Blood
  doi: 10.1182/blood-2010-07-298349
– volume: 2
  start-page: 210
  year: 1990
  ident: ref108
  article-title: Malignant rhabdoid tumor: a highly malignant childhood tumor with minimal karyotypic changes
  publication-title: Genes Chromosomes Cancer
  doi: 10.1002/gcc.2870020308
– volume: 497
  start-page: 378
  year: 2013
  ident: ref80
  article-title: The shaping and functional consequences of the microRNA landscape in breast cancer
  publication-title: Nature
  doi: 10.1038/nature12108
– volume: 357
  year: 2017
  ident: ref18
  article-title: Epigenetic plasticity and the hallmarks of cancer
  publication-title: Science
  doi: 10.1126/science.aal2380
– volume: 64
  year: 2017
  ident: ref41
  article-title: DNA methylation profiling of pediatric B-cell lymphoblastic leukemia with KMT2A rearrangement identifies hypomethylation at enhancer sites
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.26251
– volume: 37
  start-page: 1200
  year: 2013
  ident: ref43
  article-title: The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia
  publication-title: Leuk Res
  doi: 10.1016/j.leukres.2013.07.016
– volume: 17
  start-page: 2087
  year: 2016
  ident: ref50
  article-title: The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2016.08.082
– volume: 58
  start-page: 362
  year: 2015
  ident: ref129
  article-title: Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2015.02.014
– volume: 355
  start-page: 15
  year: 2012
  ident: ref84
  article-title: Progestin regulated miRNAs that mediate progesterone receptor action in breast cancer
  publication-title: Mol Cell Endocrinol
  doi: 10.1016/j.mce.2011.12.020
– volume: 18
  start-page: 49
  year: 2015
  ident: ref106
  article-title: Rhabdoid tumor predisposition syndrome
  publication-title: Pediatr Dev Pathol
  doi: 10.2350/14-07-1531-MISC.1
– volume: 409
  start-page: 860
  year: 2001
  ident: ref1
  article-title: Initial sequencing and analysis of the human genome
  publication-title: Nature
  doi: 10.1038/35057062
– volume: 19
  start-page: 808
  year: 2016
  ident: ref30
  article-title: DNA Methylation Dynamics of Human Hematopoietic Stem Cell Differentiation
  publication-title: Cell Stem Cell
  doi: 10.1016/j.stem.2016.10.019
– volume: 21
  start-page: 5193
  year: 2002
  ident: ref111
  article-title: Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1205706
– volume: 12
  start-page: 252
  year: 2012
  ident: ref94
  article-title: The blockade of immune checkpoints in cancer immunotherapy
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3239
– volume: 11
  start-page: 481
  year: 2011
  ident: ref119
  article-title: SWI/SNF nucleosome remodellers and cancer
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3068
– volume: 14
  start-page: 618
  year: 2013
  ident: ref132
  article-title: Single-cell sequencing-based technologies will revolutionize whole-organism science
  publication-title: Nat Rev Genet
  doi: 10.1038/nrg3542
– volume: 6
  start-page: 33435
  year: 2016
  ident: ref71
  article-title: DNA methylation profile of triple negative breast cancer-specific genes comparing lymph node positive patients to lymph node negative patients
  publication-title: Sci Rep
  doi: 10.1038/srep33435
– volume: 7
  start-page: 11938
  year: 2016
  ident: ref38
  article-title: Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks
  publication-title: Nat Commun
  doi: 10.1038/ncomms11938
– volume: 21
  start-page: 3598
  year: 2001
  ident: ref109
  article-title: Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.21.10.3598-3603.2001
– volume: 8
  start-page: 57
  year: 2015
  ident: ref140
  article-title: Making sense of GWAS: using epigenomics and genome engineering to understand the functional relevance of SNPs in non-coding regions of the human genome
  publication-title: Epigenetics Chromatin
  doi: 10.1186/s13072-015-0050-4
– volume: 11
  start-page: 285
  year: 2010
  ident: ref16
  article-title: Chromatin structure and the inheritance of epigenetic information
  publication-title: Nat Rev Genet
  doi: 10.1038/nrg2752
– volume: 102
  start-page: 17745
  year: 2005
  ident: ref114
  article-title: Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0509014102
– volume: 32
  start-page: 101
  year: 2016
  ident: ref144
  article-title: Epigenome Editing: State of the Art, Concepts, and Perspectives
  publication-title: Trends Genet
  doi: 10.1016/j.tig.2015.12.001
– volume: 5
  start-page: e1219008
  year: 2016
  ident: ref102
  article-title: The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2016.1219008
– volume: 9
  start-page: 387
  year: 2014
  ident: ref46
  article-title: Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3
  publication-title: Epigenetics
  doi: 10.4161/epi.27322
– volume: 16
  start-page: 803
  year: 2016
  ident: ref14
  article-title: Maintaining cell identity: PRC2-mediated regulation of transcription and cancer
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc.2016.83
– volume: 39
  start-page: 1
  year: 2016
  ident: ref95
  article-title: Immune suppressive mechanisms in the tumor microenvironment
  publication-title: Curr Opin Immunol
  doi: 10.1016/j.coi.2015.10.009
– volume: 489
  start-page: 46
  year: 2012
  ident: ref127
  article-title: ENCODE: The human encyclopaedia
  publication-title: Nature
  doi: 10.1038/489046a
– volume: 21
  start-page: 335
  year: 2015
  ident: ref42
  article-title: DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia
  publication-title: Nat Med
  doi: 10.1038/nm.3832
– volume: 144
  start-page: 646
  year: 2011
  ident: ref21
  article-title: Hallmarks of cancer: the next generation
  publication-title: Cell
  doi: 10.1016/j.cell.2011.02.013
– volume: 90
  start-page: 7
  year: 2012
  ident: ref147
  article-title: Five years of GWAS discovery
  publication-title: Am J Hum Genet
  doi: 10.1016/j.ajhg.2011.11.029
– volume: 11
  start-page: 2685
  year: 2012
  ident: ref58
  article-title: Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-12-0721
– volume: 69
  start-page: 3802
  year: 2009
  ident: ref73
  article-title: Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-08-3907
– volume: 73
  start-page: 710
  year: 1990
  ident: ref107
  article-title: Monosomy 22 in rhabdoid or atypical tumors of the brain
  publication-title: J Neurosurg
  doi: 10.3171/jns.1990.73.5.0710
– volume: 14
  start-page: R34
  year: 2012
  ident: ref81
  article-title: Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr3127
– volume: 34
  start-page: 3676
  year: 2015
  ident: ref85
  article-title: Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a
  publication-title: Oncogene
  doi: 10.1038/onc.2014.298
– volume: 22
  start-page: 5975
  year: 2002
  ident: ref112
  article-title: Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.22.16.5975-5988.2002
– volume: 183
  start-page: 1654
  year: 1959
  ident: ref3
  article-title: Canalization of development and genetic assimilation of acquired characters
  publication-title: Nature
  doi: 10.1038/1831654a0
– volume: 30
  start-page: 777
  year: 2012
  ident: ref131
  article-title: Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.2282
– volume: 147
  start-page: 423
  year: 2014
  ident: ref87
  article-title: Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-014-3037-0
– volume: 19
  start-page: 17
  year: 2011
  ident: ref19
  article-title: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2010.12.014
– volume: 27
  start-page: 450
  year: 2015
  ident: ref97
  article-title: Immune checkpoint blockade: a common denominator approach to cancer therapy
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2015.03.001
– volume: 45
  start-page: 1135
  year: 2016
  ident: ref99
  article-title: Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells
  publication-title: Immunity
  doi: 10.1016/j.immuni.2016.10.021
– volume: 7
  start-page: 562
  year: 2011
  ident: ref136
  article-title: 5-Hydroxymethylcytosine: a new kid on the epigenetic block?
  publication-title: Mol Syst Biol
  doi: 10.1038/msb.2011.95
– volume: 6
  start-page: e010243
  year: 2016
  ident: ref142
  article-title: Other side of the coin for personalised medicine and healthcare: content analysis of 'personalised' practices in the literature
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2015-010243
– volume: 49
  start-page: 808
  year: 2013
  ident: ref15
  article-title: Occupying chromatin: Polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2013.02.013
– volume: 11
  start-page: 726
  year: 2011
  ident: ref17
  article-title: A decade of exploring the cancer epigenome—biological and translational implications
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3130
– volume: 64
  year: 2017
  ident: ref121
  article-title: Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.26218
– volume: 492
  start-page: 108
  year: 2012
  ident: ref13
  article-title: EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
  publication-title: Nature
  doi: 10.1038/nature11606
– volume: 18
  start-page: 52
  year: 2017
  ident: ref138
  article-title: cepip: context-dependent epigenomic weighting for prioritization of regulatory variants and disease-associated genes
  publication-title: Genome Biol
  doi: 10.1186/s13059-017-1177-3
– volume: 7
  start-page: 6597
  year: 2017
  ident: ref72
  article-title: The Epigenetic Landscape of Promoter Genome-wide Analysis in Breast Cancer
  publication-title: Sci Rep
  doi: 10.1038/s41598-017-06790-z
– volume: 15
  start-page: 163
  year: 2005
  ident: ref5
  article-title: The key to development: interpreting the histone code?
  publication-title: Curr Opin Genet Dev
  doi: 10.1016/j.gde.2005.01.005
– volume: 70
  start-page: 596
  year: 2011
  ident: ref115
  article-title: p16INK4A and p14ARF tumor suppressor pathways are deregulated in malignant rhabdoid tumors
  publication-title: J Neuropathol Exp Neurol
  doi: 10.1097/NEN.0b013e31822146ca
– volume: 86
  start-page: 279
  year: 2010
  ident: ref104
  article-title: Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome
  publication-title: Am J Hum Genet
  doi: 10.1016/j.ajhg.2010.01.013
– volume: 236
  start-page: 567
  year: 2011
  ident: ref93
  article-title: Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity
  publication-title: Exp Biol Med (Maywood)
  doi: 10.1258/ebm.2011.011007
– volume: 368
  start-page: 2059
  year: 2013
  ident: ref32
  article-title: Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1301689
– volume: 15
  start-page: 3802
  year: 2009
  ident: ref69
  article-title: Hypermethylated genes as biomarkers of cancer in women with pathologic nipple discharge
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-08-1981
– volume: 47
  start-page: 746
  year: 2015
  ident: ref36
  article-title: Whole-genome fingerprint of the DNA methylome during human B cell differentiation
  publication-title: Nat Genet
  doi: 10.1038/ng.3291
– volume: 8
  start-page: R214
  year: 2007
  ident: ref78
  article-title: MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype
  publication-title: Genome Biol
  doi: 10.1186/gb-2007-8-10-r214
– volume: 17
  start-page: 1520
  year: 2007
  ident: ref146
  article-title: Prediction of individual genetic risk to disease from genome-wide association studies
  publication-title: Genome Res
  doi: 10.1101/gr.6665407
– volume: 17
  start-page: 173
  year: 2010
  ident: ref39
  article-title: PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2009.12.042
– volume: 324
  start-page: 929
  year: 2009
  ident: ref135
  article-title: The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain
  publication-title: Science
  doi: 10.1126/science.1169786
– volume: 120
  start-page: 4038
  year: 2012
  ident: ref47
  article-title: ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia
  publication-title: Blood
  doi: 10.1182/blood-2012-05-429050
– volume: 22
  start-page: 9
  year: 2012
  ident: ref27
  article-title: Cancer genetics and epigenetics: two sides of the same coin?
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2012.06.008
– volume: 25
  start-page: 544
  year: 2017
  ident: ref28
  article-title: Metabolic Inputs into the Epigenome
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2017.02.003
– volume: 52
  start-page: 235
  year: 2012
  ident: ref88
  article-title: Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization
  publication-title: Biotechniques
  doi: 10.2144/000113837
– volume: 117
  start-page: 553
  year: 2011
  ident: ref56
  article-title: Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma
  publication-title: Blood
  doi: 10.1182/blood-2010-04-279539
– volume: 14
  start-page: 643
  year: 2013
  ident: ref79
  article-title: Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control
  publication-title: BMC Genomics
  doi: 10.1186/1471-2164-14-643
– volume: 17
  start-page: 2101
  year: 2016
  ident: ref31
  article-title: ) Distinct Trends of DNA Methylation Patterning in the Innate and Adaptive Immune Systems
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2016.10.054
– volume: 518
  start-page: 317
  year: 2015
  ident: ref10
  article-title: Integrative analysis of 111 reference human epigenomes
  publication-title: Nature
  doi: 10.1038/nature14248
– volume: 518
  start-page: 413
  year: 2015
  ident: ref29
  article-title: Intracellular alpha-ketoglutarate maintains the pluripotency of embryonic stem cells
  publication-title: Nature
  doi: 10.1038/nature13981
– volume: 490
  start-page: 61
  year: 2012
  ident: ref64
  article-title: Comprehensive molecular portraits of human breast tumours
  publication-title: Nature
  doi: 10.1038/nature11412
– volume: 30
  start-page: 806
  year: 2016
  ident: ref34
  article-title: Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.09.014
– volume: 16
  start-page: 142
  year: 2015
  ident: ref141
  article-title: Epigenome data release: a participant-centered approach to privacy protection
  publication-title: Genome Biol
  doi: 10.1186/s13059-015-0723-0
– volume: 62
  start-page: 15
  year: 2017
  ident: ref89
  article-title: Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes
  publication-title: J Hum Genet
  doi: 10.1038/jhg.2016.89
– volume: 27
  start-page: 1160
  year: 2009
  ident: ref90
  article-title: Supervised risk predictor of breast cancer based on intrinsic subtypes
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.18.1370
– volume: 17
  start-page: 186
  year: 2010
  ident: ref40
  article-title: PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2009.12.045
– volume: 8
  start-page: 909
  year: 2016
  ident: ref75
  article-title: H3K4 acetylation, H3K9 acetylation and H3K27 methylation in breast tumor molecular subtypes
  publication-title: Epigenomics
  doi: 10.2217/epi-2016-0015
– volume: 489
  start-page: 57
  year: 2012
  ident: ref9
  article-title: An integrated encyclopedia of DNA elements in the human genome
  publication-title: Nature
  doi: 10.1038/nature11247
– volume: 7
  start-page: 57327
  year: 2016
  ident: ref60
  article-title: Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.10033
– volume: 100
  start-page: 57
  year: 2000
  ident: ref6
  article-title: The hallmarks of cancer
  publication-title: Cell
  doi: 10.1016/S0092-8674(00)81683-9
– volume: 11
  start-page: R27
  year: 2009
  ident: ref83
  article-title: MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr2257
– volume: 29
  start-page: 440
  year: 2016
  ident: ref133
  article-title: Intratumoral Heterogeneity of the Epigenome
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.03.009
– volume: 122
  start-page: 2983
  year: 2012
  ident: ref122
  article-title: A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers
  publication-title: J Clin Invest
  doi: 10.1172/JCI64400
– volume: 33
  start-page: 933
  year: 2014
  ident: ref117
  article-title: Activation of beta-catenin/TCF targets following loss of the tumor suppressor SNF5
  publication-title: Oncogene
  doi: 10.1038/onc.2013.37
– volume: 127
  start-page: 713
  year: 2016
  ident: ref59
  article-title: Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
  publication-title: Blood
  doi: 10.1182/blood-2015-09-665018
– volume: 355
  start-page: 1324
  year: 2017
  ident: ref100
  article-title: PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D
  publication-title: Science
  doi: 10.1126/science.aah6893
– volume: 35
  start-page: 933
  year: 2011
  ident: ref105
  article-title: Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0b013e3182196a39
– volume: 121
  start-page: 5131
  year: 2013
  ident: ref23
  article-title: Perspectives and future directions for epigenetics in hematology
  publication-title: Blood
  doi: 10.1182/blood-2013-04-427724
– volume: 9
  start-page: 1936
  year: 2015
  ident: ref96
  article-title: Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
  publication-title: Mol Oncol
  doi: 10.1016/j.molonc.2015.10.008
– volume: 32
  start-page: 2959
  year: 2014
  ident: ref92
  article-title: Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2013.55.0491
– volume: 5
  start-page: 813
  year: 2013
  ident: ref86
  article-title: miR-342 is associated with estrogen receptor-alpha expression and response to tamoxifen in breast cancer
  publication-title: Exp Ther Med
  doi: 10.3892/etm.2013.915
– volume: 44
  start-page: 1236
  year: 2012
  ident: ref35
  article-title: Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia
  publication-title: Nat Genet
  doi: 10.1038/ng.2443
– volume: 29
  start-page: 598
  year: 2015
  ident: ref37
  article-title: A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact
  publication-title: Leukemia
  doi: 10.1038/leu.2014.252
– volume: 18
  start-page: 5526
  year: 2012
  ident: ref137
  article-title: Molecular pathways: the complexity of the epigenome in cancer and recent clinical advances
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-12-2037
– volume: 15
  start-page: 1974
  year: 1995
  ident: ref49
  article-title: The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.15.4.1974
– volume: 167
  start-page: 1897
  year: 2016
  ident: ref7
  article-title: The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery
  publication-title: Cell
  doi: 10.1016/j.cell.2016.12.002
– volume: 90
  start-page: 724
  year: 2010
  ident: ref118
  article-title: Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets
  publication-title: Lab Invest
  doi: 10.1038/labinvest.2010.66
– volume: 168
  start-page: 801
  year: 2017
  ident: ref33
  article-title: CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression
  publication-title: Cell
  doi: 10.1016/j.cell.2017.01.021
– volume: 5
  start-page: 4
  year: 2017
  ident: ref12
  article-title: MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches
  publication-title: Front Pediatr
  doi: 10.3389/fped.2017.00004
– volume: 110
  start-page: 7922
  year: 2013
  ident: ref120
  article-title: Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1303800110
– volume: 9
  start-page: 217
  year: 2009
  ident: ref68
  article-title: Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-9-217
– volume: 155
  start-page: 934
  year: 2013
  ident: ref128
  article-title: Super-enhancers in the control of cell identity and disease
  publication-title: Cell
  doi: 10.1016/j.cell.2013.09.053
– volume: 24
  start-page: 1181
  year: 2017
  ident: ref145
  article-title: Targeted Protein Degradation: from Chemical Biology to Drug Discovery
  publication-title: Cell Chem Biol
  doi: 10.1016/j.chembiol.2017.05.024
– volume: 16
  start-page: 569
  year: 2015
  ident: ref124
  article-title: Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(15)70114-2
– volume: 8
  start-page: 56
  year: 2016
  ident: ref143
  article-title: Epigenetic drugs: from chemistry via biology to medicine and back
  publication-title: Clin Epigenetics
  doi: 10.1186/s13148-016-0222-5
– volume: 28
  start-page: e563
  year: 2010
  ident: ref67
  article-title: BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2010.30.1010
– volume: 17
  start-page: 72
  year: 2016
  ident: ref134
  article-title: Single-cell epigenomics: powerful new methods for understanding gene regulation and cell identity
  publication-title: Genome Biol
  doi: 10.1186/s13059-016-0944-x
– volume: 17
  start-page: 2075
  year: 2016
  ident: ref91
  article-title: Epigenomic Deconvolution of Breast Tumors Reveals Metabolic Coupling between Constituent Cell Types
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2016.10.057
– volume: 18
  start-page: 1238
  year: 2004
  ident: ref52
  article-title: Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self-renewal
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2403396
– volume: 25
  start-page: 478
  year: 2015
  ident: ref55
  article-title: Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers
  publication-title: Genome Res
  doi: 10.1101/gr.180240.114
– volume: 37
  start-page: 922
  year: 2013
  ident: ref44
  article-title: High expression of Musashi-2 indicates poor prognosis in adult B-cell acute lymphoblastic leukemia
  publication-title: Leuk Res
  doi: 10.1016/j.leukres.2013.05.012
– volume: 8
  start-page: 1974
  year: 2014
  ident: ref51
  article-title: Identification of a dynamic core transcriptional network in t(8;21) AML that regulates differentiation block and self-renewal
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2014.08.024
– volume: 7
  start-page: 11725
  year: 2017
  ident: ref24
  article-title: Time-resolved analysis of DNA-protein interactions in living cells by UV laser pulses
  publication-title: Sci Rep
  doi: 10.1038/s41598-017-12010-5
– volume: 153
  start-page: 38
  year: 2013
  ident: ref26
  article-title: Interplay between the cancer genome and epigenome
  publication-title: Cell
  doi: 10.1016/j.cell.2013.03.008
– volume: 7
  start-page: 444
  year: 2001
  ident: ref53
  article-title: AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia
  publication-title: Nat Med
  doi: 10.1038/86515
– volume: 45
  start-page: 1122
  year: 2016
  ident: ref98
  article-title: Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
  publication-title: Immunity
  doi: 10.1016/j.immuni.2016.10.032
– volume: 59
  start-page: 1155
  year: 2012
  ident: ref123
  article-title: Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.24315
– volume: 8
  start-page: 34
  year: 2016
  ident: ref76
  article-title: Global histone modification profiling reveals the epigenomic dynamics during malignant transformation in a four-stage breast cancer model
  publication-title: Clin Epigenetics
  doi: 10.1186/s13148-016-0201-x
– volume: 29
  start-page: 379
  year: 2016
  ident: ref125
  article-title: Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.02.001
– volume: 9
  start-page: e111840
  year: 2014
  ident: ref62
  article-title: Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0111840
– volume: 463
  start-page: 596
  year: 2010
  ident: ref8
  article-title: Project set to map marks on genome
  publication-title: Nature
  doi: 10.1038/463596b
– volume: 8
  start-page: S6
  year: 2011
  ident: ref130
  article-title: Development and applications of single-cell transcriptome analysis
  publication-title: Nat Methods
  doi: 10.1038/nmeth.1557
– volume: 109
  start-page: 27
  year: 2008
  ident: ref70
  article-title: Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-007-9620-x
– volume: 11
  start-page: 513
  year: 2007
  ident: ref61
  article-title: Role of the polycomb repressive complex 2 in acute promyelocytic leukemia
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2007.04.009
– volume: 6
  start-page: 66
  year: 2014
  ident: ref126
  article-title: Pan-cancer patterns of DNA methylation
  publication-title: Genome Med
  doi: 10.1186/s13073-014-0066-6
– volume: 41
  start-page: 10
  year: 2012
  ident: ref4
  article-title: The epigenotype. 1942
  publication-title: Int J Epidemiol
– volume: 409
  start-page: 934
  year: 2001
  ident: ref2
  article-title: A physical map of the human genome
  publication-title: Nature
  doi: 10.1038/35057157
– volume: 65
  start-page: 10192
  year: 2005
  ident: ref113
  article-title: Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-05-1896
– volume: 7
  start-page: 1225
  year: 2012
  ident: ref66
  article-title: BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer
  publication-title: Epigenetics
  doi: 10.4161/epi.22561
– volume: 97
  start-page: 13796
  year: 2000
  ident: ref110
  article-title: Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.250492697
– volume: 8
  start-page: 12855
  year: 2017
  ident: ref20
  article-title: AML associated oncofusion proteins PML-RARA, AML1-ETO and CBFB-MYH11 target RUNX/ETS-factor binding sites to modulate H3ac levels and drive leukemogenesis
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.14150
– volume: 46
  start-page: 427
  year: 2014
  ident: ref22
  article-title: Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4
  publication-title: Nat Genet
  doi: 10.1038/ng.2928
SSID ssj0035897
Score 2.673423
SecondaryResourceType review_article
Snippet Defects in chromatin modifiers and remodelers have been described both for hematological and solid malignancies, corroborating and strengthening the role of...
SourceID plos
doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage e1007362
SubjectTerms Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Biology
Biology and life sciences
Biomarkers, Tumor - genetics
Breast cancer
Cancer
Cancer genetics
Cancer research
Cancer therapies
Chromatin
Chromatin Assembly and Disassembly - genetics
Chromatin remodeling
Consortia
Deoxyribonucleic acid
Disease
Disease Progression
DNA
DNA methylation
DNA Methylation - genetics
Enzyme Inhibitors - pharmacology
Enzyme Inhibitors - therapeutic use
Enzymes - genetics
Enzymes - metabolism
Epigenesis, Genetic - drug effects
Epigenetic inheritance
Epigenetics
Epigenomics - methods
Etiology
Forecasts and trends
Gene expression
Gene Expression Regulation, Neoplastic
Genetic research
Genomes
Histone Code - genetics
Humans
Leukemia
Medicine and Health Sciences
MicroRNAs - genetics
miRNA
Molecular Targeted Therapy - methods
Mutation
Neoplasms - diagnosis
Neoplasms - drug therapy
Neoplasms - genetics
Patients
Prognosis
Review
Transcription factors
Tumorigenesis
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9RAEF_kUPBF_G60aiyCT7FJ9tu3WiwKeoofpW_LZndTCyV3XO4E_3tndnOhkUL74Gv2l0B-M7s7k8z-hpBX3Ja-9LQpJMTKBWPMF6ptXBGEFV44pm1sB3T8Sc7n6uREf73Q6gtrwpI8cCJuP3hW47akawuZhHLaOupgGwzM60o1UWwbop5tMpXWYMpVaqvCOS0kpPXDoTkqq_3BRm-WYKBYI0BFPdmUonb_uELPlueL_rLw898qygvb0tFdcmeIJ_OD9B73yI3Q3Se3UofJPw_I3iFadZWHJapu4oHF_m3-OX5FyCFcxZLZh-Tn0fsfhx-KoS1C4WQt1oWmwK3jrGa28ZxaaoHPpuRtsBWEE9Q5SAJoq7TVqmXBV6GVFeNlsMIFbil9RGbdogs7JA9wmdpWeS4Ua2iwmnvdQEzRhrLRrMkI3fJi3KAZjq0rzk38ESYhd0ivaZBNM7CZkWK8a5k0M67Av0PKRywqXscL4Adm8ANzlR9k5AUazKTjo-O8NQecQVIH60yVkb2IQNWLDstqTu2m783HL8fXAH2fXwf0bQJ6PYDaBXDm7HDeAZhHya0JcneChAnuJsM76INb6npTwzKtBB6OhDu3fnn58MtxGB-K9XRdWGwQw2tVwuwA8h8nNx7pr7WSEETKjMiJg0_sMx3pzn5FZXKO2YYQT_6HQZ-S2xCcqliWJ3fJbL3ahGfkpvu9PutXz-N0_wsz21YS
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Public Library of Science (PLoS) Journals Open Access
  dbid: FPL
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELbQAhKX8qYpBUKFxCmQxG9upWIFUlkqHlVvlmM7UKnKrja7SPx7ZpxsIFUryjX-vIo_eybfrMdjQl5wm_vc0yqToJUzxpjPVF25LAgrvHBM23gd0PGhnM3UyYk--hMontvBp7J43XP6agGExj396HKvl1QITOGaHh1uPC_lSsv-eNxlPUefn1ilf_DFk8XZvL1IaJ7Pl_zrAzS9_b-vfods9VIz3e_Wxl1yLTT3yM3u8slf98neAU74Mg0LLMiJZxnbN-nH-AdDCkoWs2kfkG_Td18P3mf9jQmZk6VYZZoC7Y6zktnKc2qpBaqrnNfBFqA0qHMQH9BaaatVzYIvQi0LxvNghQvcUvqQTJp5E7ZJGuAxtbXyXChW0WA197oCuVGHvNKsSgjdEGlcX04cb7U4M3GPTEJY0Q3T4OhNP_qEZEOvRVdO4x_4tzhHAxaLYccHQLPpbcsEz0pULrq0EGwqp62jDpRSYF4XqhIJeYYzbLqTpYNJm33OIN4DF1QkZC8isCBGgxk33-26bc2HT8dXAH2ZXQX0eQR62YPqOXDmbH8UApjHalwj5O4ICbbvRs3buGg31LWmBA-uBJ6bhJ6bhXxx8_OhGX8UU-2aMF8jhpcq55wC-Y-6dT_QX2olQV_KhMiRRYzmZ9zSnP6IRcs5BiJC7Fz-xo_JLVCjKubhyV0yWS3X4Qm54X6uTtvl02jpvwG8eFEu
  priority: 102
  providerName: Public Library of Science
Title Cancer epigenetics: Moving forward
URI https://www.ncbi.nlm.nih.gov/pubmed/29879107
https://www.proquest.com/docview/2070861998
https://www.proquest.com/docview/2052805532
https://pubmed.ncbi.nlm.nih.gov/PMC5991666
https://doaj.org/article/ed42215192a4488c9ac3c741e4d918b6
http://dx.doi.org/10.1371/journal.pgen.1007362
Volume 14
WOSCitedRecordID wos000440484200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1553-7404
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0035897
  issn: 1553-7404
  databaseCode: DOA
  dateStart: 20050101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 1553-7404
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0035897
  issn: 1553-7404
  databaseCode: M7P
  dateStart: 20050701
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1553-7404
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0035897
  issn: 1553-7404
  databaseCode: 7X7
  dateStart: 20050701
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1553-7404
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0035897
  issn: 1553-7404
  databaseCode: BENPR
  dateStart: 20050701
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 1553-7404
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0035897
  issn: 1553-7404
  databaseCode: PIMPY
  dateStart: 20050701
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVATS
  databaseName: Public Library of Science (PLoS) : Open Access Journals [open access]
  customDbUrl:
  eissn: 1553-7404
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0035897
  issn: 1553-7404
  databaseCode: FPL
  dateStart: 20050701
  isFulltext: true
  titleUrlDefault: http://www.plos.org/publications/
  providerName: Public Library of Science
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdYBxIvfMMKo5QJiadAEtuxzQvaplVM2ko0YOqeIsdxxqQpKU2LxH_PneMGgiaYxEse4kuU3J0vv7vcByGvuA6LsKB5IAArB4yxIpBlbgKb6KRIDFPajQM6PRLTqZzNVOoDbo1Pq1zbRGeoi9pgjBwjIYC-sSLs_fxbgFOj8O-qH6GxQTaxSwJ1qXvp2hJTLtvhKpzTQIBz70vnqIjeekm9mYOYXKYATeLep8l18O_s9GB-WTdXgdA_cyl_-zhN7v7va90jdzwsHe-2enSf3LDVA3KrHVT54yHZ2UflWIztHJt3Yt1j82587IIRY0C9mHn7iHyZHHze_xD46QqBEXGyDBQFERnOYqbzglNNNYglD3lpdQSohBoDvgQtpdJKlswWkS1FxHhodWIs15Q-JoOqruwWGVs4TXUpC55IllOrFS9UDtCktGGuWD4kdM3YzPjW4zgB4zJz_9MEuCDta2YojsyLY0iC7qp523rjH_R7KLOOFhtnuxP14jzz-zCzBYsR5ahYg2MqjdKGGkBVlhUqknkyJC9Q4llbhdpt_2yXM_ANwVxFQ7LjKLB5RoXZOed61TTZ4cfTaxB9ml6H6KRH9NoTlTXwzGhfNgGcx85dPcrtHiXYCdNb3kIlXrOuyX6pHly5Vs6rl192y3hTTMurbL1CGh7LELYXMP9Juw869sdKCsCiYkhEb4f05NNfqS6-ugbnHJ2WJHn698d6Rm4DepUub09sk8FysbLPyU3zfXnRLEZkQ8yEO8oR2dw7mKYnIxdwgeMkPRo5SwEr6eFxevYT-rBr-A
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELaqBQQX3tCFQkMF4hRIYjuxkRAqhaqrbpcK2qq34NhOqVQly2YX1D_Fb2TGeUBQBb30wDWerLzz8jfOPAh5ylVgAkMzPwGs7DPGjC_yTPs2VrGJNZPKjQM6GCeTiTg8lLtL5EdbC4Npla1PdI7alBrvyPEmBNA3VoS9mX71cWoUfl1tR2jUarFtT79DyFa9Hr0D-T6Los33extbfjNVwNdJFM99SWFrmrOIqcxwqqiC7WQBz60K4TSmWgOGprmQSoqcWRPaPAkZD6yKteUKL0DB5V8CGBEJlyq423p-ykU9zIVz6idUBk2pHk3Cl41mvJiCWrjMBBpHvaPQTQzozoXB9KSszgK9f-Zu_nYYbt7439h4k1xvYLe3XtvJLbJki9vkSj2I8_QOWdtA5Z95dorNSbGus3rl7bjLFg9QPWYW3yX7F7LBe2RQlIVdJp6Fx1TlwvBYsIxaJbmRGUCv3AaZZNmQ0FaQqW5aq-OEj5PUfS9MIMSq_2aK4k8b8Q-J3701rVuL_IP-LepIR4uNwd2DcnaUNn4mtYZFiOJkpCDwFloqTTWgRsuMDEUWD8kqalhaV9l27i1d5wxiX3DH4ZCsOQpsDlJg9tGRWlRVOvpwcA6iT5PzEH3sET1viPISeKZVUxYCnMfOZD3KlR4l-EHdW15Go2lZV6W_VB3ebI3h7OUn3TL-KKYdFrZcIA2PRADmDMy_X9tdx_5IigSwdjIkSc8ie_LprxTHX1wDd45BWRw_-Pu2VsnVrb2dcToeTbYfkmuA1IXLUUxWyGA-W9hH5LL-Nj-uZo-dF_LI54u215-6LsM1
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Zb9QwELaq5RAv3NCFQkMF4ik0ie3YRkKotKxYtSwrjqpvwXGcUqlKls0uqH-NX8eMc0BQBX3pA6_xZOUdz_GNMwchj7kOsiCjqS8AK_uMscyXeWp8G-s4iw1T2o0D2t8Tk4k8OFDTFfKjrYXBtMrWJjpDnZUG78jxJgTQN1aEbeZNWsR0Z_Ry9tXHCVL4pbUdp1GLyK49-Q7hW_VivANn_SSKRq8_br_xmwkDvhFRvPAVhW0aziKm04xTTTVsLQ14bnUInpkaA3ia5lJpJXNms9DmImQ8sDo2lmu8DAXzf0Fg03KXNjhtvQDlsh7swjn1BVVBU7ZHRbjZSMmzGYiIy1KgcdRzi256QOcjBrPjsjoNAP-Zx_mbYxxd-59Zep1cbeC4t1Xrzw2yYoub5FI9oPPkFtnYRqWYe3aGTUux3rN67r11lzAeoH3MOL5NPp3LBu-QQVEWdpV4Fh5TncuMx5Kl1GrFM5UCJMttkCqWDgltDzUxTct1nPxxnLjviAJCr_pvJigKSSMKQ-J3b83qliP_oH-F8tLRYsNw96CcHyaN_UlsxiJEdyrSEJBLo7ShBtCkZZkKZRoPyTpKW1JX33ZmL9niDGJiMNPhkGw4CmwaUqCsHOplVSXjd_tnIPowOQvR-x7R04YoL4FnRjflIsB57FjWo1zrUYJ9NL3lVVSglnVV8kvs4c1WMU5fftQt449iOmJhyyXS8EgGoNrA_Lu1Dnbsj5QUgMHFkIiedvbOp79SHH1xjd05BmtxfO_v21onl0FNk73xZPc-uQIAXrrURbFGBov50j4gF823xVE1f-gMkkc-n7e6_gRAxsvy
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cancer+epigenetics%3A+Moving+forward&rft.jtitle=PLoS+genetics&rft.au=Nebbioso%2C+Angela&rft.au=Tambaro%2C+Francesco+Paolo&rft.au=Dell%E2%80%99Aversana%2C+Carmela&rft.au=Altucci%2C+Lucia&rft.date=2018-06-07&rft.issn=1553-7404&rft.eissn=1553-7404&rft.volume=14&rft.issue=6&rft.spage=e1007362&rft_id=info:doi/10.1371%2Fjournal.pgen.1007362&rft.externalDBID=n%2Fa&rft.externalDocID=10_1371_journal_pgen_1007362
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1553-7404&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1553-7404&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1553-7404&client=summon